Tag: cancer

  • Miscellaneous Cancer Tests

    Serum lactic dehydrogenase. Serum LDH levels are sometimes elevated in extensive carcinomatosis, often without any obvious reason. This is especially true in lymphoma, where it may be abnormal in up to 50% cases. However, LDH levels can be elevated in many conditions, which considerably lessens its usefulness in cancer diagnosis.

    Carcinoma antigen 19-9. CA 19-9 is a carbohydrate antigen segment of a glycoprotein that appears to be a sialylated derivative of the Lewis A blood group. It is detected by monoclonal antibody immunoassay and is reasonably (but not highly) specific for GI tract origin (Table 33-14).

    CA 19-9 in various conditions

    Table 33-14 CA 19-9 in various conditions

    Currently, although there is considerable research activity, CA 19-9 assay is not being widely used. Although it has reasonably good sensitivity in pancreatic carcinoma, it does not detect these tumors early enough to improve their current dismal prognosis, and it is not specific for pancreatic neoplasms. It might be useful in the workup of patients when pancreatic or gastric carcinoma is a possibility and more informative diagnostic procedures (e.g., ultrasound or CT) are not available or do not provide a definite answer. A definitely elevated CA 19-9 level result would favor carcinoma of GI or GI accessory organs. The specimen has to be sent to a reference laboratory in most cases, and the results would not be available for several days. The CA 19-9 assay could be used to follow pancreatic carcinomas after surgical resection to detect recurrence, but the question then arises as to what could be done if it does recur. Finally, CA 19-9 has been used in addition to CEA in order to detect recurrence of colon cancer. In some cases, CA 19-9 values become elevated before CEA, and the combination of the two tests is said to be more reliable than either test alone. However, at present CA 19-9 is not widely used for this purpose. As noted in Table 33-14, CA 19-9 may be elevated in some persons who do not have cancer. Also, 5%–10% of the population is Lewis A (blood group) negative and will not react with CA 19-9, even if they have cancer.

    Centocor CA 15-3 and Hybritech CA 549. CA 15-3 detects membrane antigens against human milk globules. It is said to be elevated in 57% of preoperative breast cancer patients, 75% (68%–80%) of patients with breast cancer with metastases, 3%–9% of patients with benign breast tumors, 4.5%–10.5% of patients with various nonmalignant conditions, and 1% of clinically normal persons. It is said to correlate with the clinical course of about 75% of patients with metastatic breast cancer, more frequently correlating with tumor progression than tumor regression. CA 549 detects any antigen present both in milk fat globule membranes and also in tumor cytoplasm. CA 549 is reported to be abnormal in 53%–90% of patients with metastatic breast cancer and 1%–13% of patients with benign breast disease. Certain other metastatic tumors are also detected.

    Flow cytometry test for bladder cancer. One study reports that standard urine cytology detected 58% of high-grade bladder carcinomas and 33% of low-grade bladder carcinomas. Flow cytometry methods detected 76% of low-grade tumors and 100% of high-grade tumors. However, one study suggests that the technique is not reliable when intravesical chemotherapy is given (which is also the problem with standard urine cytology).

  • Effusions and Tests for Cancer

    In general, when an effusion occurs, the problem is differentiation among neoplastic, infectious, and fluid leakage etiologies. Effusions due to neoplasms or infection are frequently termed exudates and those due to hydrostatic leakage from vessels are called transudates. Several criteria have been proposed to separate transudates and exudates and to differentiate among the three major diagnostic categories. Most work has been done on pleural fluids. The significance of tests performed on pleural fluid may not be the same if the tests are performed on ascitic fluid.

    Etiology. The two most common causes of pleural effusions are congestive heart failure and neoplasm. Infection (tuberculosis or pneumonia) is the third most frequent etiology. In some cases it is necessary to establish the diagnosis of chylous effusion. Chylous effusions usually have a triglyceride content of 110 mg/100 ml (1.2 mmol/L) or greater and are usually more than twice the serum triglyceride value. Centrifugation does not clear a supernate area, and it may be possible to demonstrate fat droplets with a fat stain such as Sudan III. Another problem that occasionally arises is to differentiate urine from effusion fluid. Urine almost always has a creatinine concentration twice that of serum or more, whereas effusion fluid usually has the same creatinine concentration as the patient’s serum or at least is not elevated as much as twice the serum level. Rarely, recurrent fluid in or draining from the nose or ear has to be differentiated between cerebrospinal fluid (CSF) leakage from the central nervous system (CNS) subarachnoid space versus a serum transudate or local mucosa secretion. The usual diagnostic test is injection of a radioisotope into the CSF and subsequent analysis of a specimen of the draining fluid. Some other tests may be the ratio between serum and CSF total protein (which is usually more than 100), serum albumin/CSF albumin ratio (which is usually over 200), and serum prealbumin/ CSF prealbumin ratio (which is usually over 14).

    Specific gravity. Exudates typically have a specific gravity of 1.016 or more and transudates less than 1.015. One study found about 25% error in misclassification of either transudates or exudates.

    Protein content. Pleural fluid total protein levels higher than 3 gm/100 ml (30 gm/L) are characteristic of exudates. Transudates have total protein content of less than 3 and usually less than 2 gm. Two studies found that 8% of exudates and 11%–15% of transudates would be misdiagnosed if 3 gm/100 ml were used as the dividing line. Most exudates that were misdiagnosed as transudates were neoplastic. A pleural fluid/serum protein ratio of 0.5 may be a slightly better dividing line; exudates usually have a ratio greater than 0.5. With this criterion, accuracy in identifying transudates improved, but 10% of the exudates, mostly of malignant origin, were incorrectly classified as transudates. Pulmonary infarct, rheumatoid-collagen diseases, acute pancreatitis, cirrhosis with high-protein ascites (12%–19% of cases), and other conditions may produce effusions with protein content compatible with exudates.

    Several investigators report that the albumin gradient between serum and ascitic fluid differentiates between transudate or exudate nature of ascites better than total protein content. In one study, total protein ascitic values produced 64% overlap between etiologies of the exudate and transudate groups, whereas the serum albumin-ascitic fluid albumin gradient (SA-AFAG) produced 38% overlap. Another study produced only 7% overlap. The SA-AFAG consists of subtracting the ascitic albumin value from the serum albumin value. A SA-AFAG value of 1.1 gm/100 ml (11 gm/L) or more suggests a transudate, usually caused by portal hypertension due to cirrhosis. A SA-AFAG value less than 1.1 gm suggests an exudate but will not differentiate malignancy from infection or inflammation and occasionally may occur in nonmalignant, nonalcoholic cirrhosis. Another problem may arise when two conditions coexist such as liver metastases in a patient with cirrhotic ascites.

    Patients with ascites due to cirrhosis develop bacterial infection of the ascitic fluid without known cause (“spontaneous bacterial peritonitis”) in about 15% of cases (range, 4%–20%). Spontaneous ascitic infection typically has an ascitic total protein less than 1.0 gm/100 ml (10 gm/L). Other types of ascitic fluid infection (“secondary peritonitis”) usually have an ascitic fluid total protein level greater than 1.0 gm/100 ml, ascitic fluid glucose less than 50mg/100 ml (2.78 mmol/L), and more than one organism obtained by culture. Gram stains of ascitic fluid are said to be positive in only 10% of spontaneous peritonitis, but more frequently in peritoneal fluid due to intestinal perforation.

    Effusion lactic dehydrogenase. A pleural fluid to serum lactic dehydrogenase (LDH) ratio greater than 0.6 is reported to be typical of exudates. One study found that most transudates were correctly identified but that nearly 30% of exudates were misclassified.

    Combinations of criteria. The more criteria that favor one category as opposed to the other, the more accurate the results become. One study found that the combination of pleural fluid/serum protein ratio and pleural fluid/serum LDH ratio correctly identified most transudates and exudates.

    pH. An effusion fluid pH higher than 7.40 usually is associated with a transudate, whereas a pH of less than 7.40 is more likely to be an exudate caused by infection, inflammation, or tumor.

    Glucose. A pleural fluid glucose level more than 10 mg/100 ml below lower limits of normal for serum, especially when the actual pleural fluid value is less than 20 mg/100 ml, is reported to be suggestive of neoplasm or infection. Possibly 15%–20% of malignant effusions have decreased glucose levels. Patient hypoglycemia, rheumatoid arthritis, and infection are other etiologies.

    Cell count and differential. In ascites, a total WBC count of 250 mm 3 or more strongly suggests infection, especially when neutrophils exceed 50% of total WBCs (some use 500 WBCs as the cutoff point). In any body fluid, presence of many segmented granulocytes suggests infection (empyema); many mononuclear cells raise the question of lymphoid malignancy, carcinoma, or tuberculosis. However, several investigators state that sufficient exceptions occur to severely limit the usefulness of differential counts in the diagnosis of individual patients. One study reported that peripheral blood WBCs did not affect ascitic fluid WBC counts.

    Culture. Culture is frequently performed for tuberculosis, fungus, and ordinary bacteria. Pleural fluid culture for tuberculosis is said to be positive only in approximately 25% of known cases of tuberculosis effusion. Some believe that tuberculosis culture should be limited to high-risk patients or patients who have a positive skin test result. Whereas tuberculosis is an important cause of idiopathic pleural effusion, although less common in the United States than in the past, fungus is an uncommon cause of pulmonary infection except in patient groups with compromised immunologic defenses. Studies have shown about 85% sensitivity of culture in ascitic infection using blood culture bottles inoculated at the time of paracentesis versus only 50% sensitivity when ascitic fluid is streaked on agar plates or inoculated onto broth media in the laboratory.

    Cytology. About 30%–40% (literature range, 25%–52%) of all pleural effusions are associated with neoplasms. About 35%–40% are caused by lung carcinoma (most often adenocarcinoma), and about 20%–25% are due to breast carcinoma, with lymphoma or leukemia, ovary, or unknown primary in third place. Cytologic study is reported to detect tumor cells in about 50%–65% (literature range, 30%–98%) of patients with malignant pleural effusions. One problem that sometimes occurs is poor cytologic preparations due to blood in the pleural fluid. We have obtained better results by using cytologic spray fixative when the cytologic slides are prepared rather than fixing the slides by the usual technique of dipping them in alcohol.

    Pleural effusion carcinoembryonic antigen (CEA) CEA is discussed in detail elsewhere. Pleural fluid CEA levels may be elevated in various malignant and some benign conditions. When a cutoff level approximately 4 times the upper reference limit (corresponding to 10 ng/ml with the Hansen technique, whose upper normal limit is 2.5 ng/ml) is used, most elevations due to nonmalignant cause are eliminated (< 5% false positive results; literature range, 1%–12%). About 35%–50% of malignancies are detected (25%–89%). Therefore, CEA by itself is less sensitive than cytology. Addition of CEA to cytology (using a CEA cutoff value sufficient to exclude benign disease) improves detection of malignancy about 10%–15% over cytology alone. Carcinoembryonic antigen assay can also be used for ascitic fluid, with similar results.

    Tests for cancer-related ascites Among many tests proposed to detect malignancy causing ascites or accumulation of peritoneal fluid are the serum albumin-ascitic albumin gradient (SAAAG), ascitic fluid cholesterol, ascitic fluid fibronectin, cytology, CEA, flow cytometry (FCM), CA 125, and the monoclonal antibody immunohistochemical stains. In general, SAAAG less than 1.1 appears to be the best single overall relatively simple test, with sensitivity in detecting malignancy about 93% (range, 85%–100%) and accuracy of about 95% (range, 93%–97%). The main drawback is inability to detect those cases of ascites due to liver metastases or hepatocellular carcinoma without peritoneal implants (since the intrahepatic malignant cells are infrequently in direct contact with ascitic fluid) or differentiate these cases from ascities due to cirrhosis. Ascitic fluid cholesterol greater than 45 in two reports had 90%–100% sensitivity, but not enough studies are available, and patients with cardiac or pancreatic-origin ascities may in some cases have elevated ascitic cholesterol. Fibronectin had sensitivity of about 90% (range, 86%–93%) in three studies, but specimens usually would have to be sent to a reference laboratory. Serum CEA has been discussed earlier. Ascitic fluid CEA has a reported sensitivity of about 50% (range, 36%–80%). Cytology of ascitic fluid has sensitivity of about 60% (range, 40%–70%). Adding CEA assay to cytology increases cytologic sensitivity about 10%–20%. FCM estimates the amount of nucleic acid in cell nuclei; in general, an abnormal quantity of nucleic acid (aneuploidy) suggests malignancy. In one study, FCM aneuploidy increased the number of patients found to have malignancy by 39% over results of cytology alone. However, not all aneuploid cells are malignant, and not all malignant cells are aneuploid . Therefore, flow cytometry has been reported to produce about 30% (range, 0%–43%) false negative results and some false positive results. CA 125 assay in serum is discussed earlier in this chapter. It has much less often been applied to ascitic fluid. In a few reports, CA 125 has been reported to increase detection of ovarian carcinoma (and occasionally, uterine or fallopian tube carcinoma) over detection rates from cytology with or without CEA. Disadvantages of ascitic fluid CA 125 assay is frequent elevation of the antigen in ascities due to cirrhosis and to some extent with endometriosis. Monoclonal antibody stains against various tumor antigens have been applied to cell blocks or smears or by FCM in body cavity fluid specimens. The most useful antibodies in peritoneal fluid appear to be CA 125 and B72.3 for ovarian carcinoma, and EMA and CEA for adenocarcinoma in general. In one representative study, peritoneal washings from patients with stage I and II ovarian carcinoma were positive by cytology in 41% of patients and by immunohistology in 56%. In stage III and IV ovarian carcinoma, immunohistology also added an additional 14% positive patients to results from cytology.

    Peritoneal lavage for traumatic injury. Although this subject does not involve cancer, it does fit with discussions on tests for effusions, and thus it is included here. The standard criteria leading to high expectation of intraabdominal bleeding are one or more of the following: aspiration of gross blood (the quantity required is not uniform, but at least 10 ml or 20 ml are most often mentioned), fluid with an RBC count greater than 100,000/mm 3, or a WBC count greater than 500/mm 3. Other criteria that have been proposed but that are not widely accepted are abdominal fluid bilirubin or creatinine values higher than serum values or elevated effusion amylase. In most series the standard criteria detect significant intraabdominal bleeding in about 90% of cases and falsely suggest significant bleeding in about 10%–15% of cases (some of these patients may have bleeding that retrospectively is not considered sufficient to warrant laparotomy). CT scanning has proved extremely useful in trauma patients, with a sensitivity equal to that of lavage and a false positive rate significantly less than that of lavage. In addition, CT can often demonstrate what organs are affected.

    General considerations. Three anticoagulated tubes of effusion fluid should be sent to the laboratory, one tube containing ethylenediamine tetraacetic acid (EDTA) anticoagulant, one tube containing 0.05% sodium polyanetholesulfonate (SPS; Liquoid), and the third containing heparin. The EDTA tube is used for cell count and differential, the SPS tube for culture, and the heparinized tube for cytology. Without anticoagulant there may be sufficient protein in the specimen to induce spontaneous clotting, which can trap WBCs and bacteria and produce erroneous cell counts and falsely negative cultures. Some use of the heparinized tube both for culture and for cytology, but too much heparin may inhibit bacterial growth. Nonanticoagulated effusion fluid should also be sent to perform biochemical tests. As noted previously, when the effusion is ascites it is better to inoculate blood culture bottles when the ascitic fluid is obtained rather than to perform routine culture methods.

  • Ovary

    Cancer antigen 125. The cancer antigen 125 (CA 125) test uses an antibody against antigen from tissue culture of an ovarian tumor cell line. Various published evaluations report sensitivity of about 75%–80% in patients with ovarian carcinoma. There is also an appreciable incidence of elevated values in nonovarian malignancies and in certain benign conditions (see the box on this page). Test values may transiently increase during chemotherapy.
    CA 125 has been advocated to monitor patients for recurrence of ovarian carcinoma after initial surgery, similar to the use of CEA after surgery for colon carcinoma. With both CA 125 and CEA there are sufficient normal results (at least 20%) in patients with cancer and sufficient abnormal results in other tumors and in benign conditions to preclude use of the test to screen for tumor under most circumstances. Studies in patients after therapy showed that up to 90% of patients with persistent CA 125 level elevation after surgery had residual tumor, and that nearly all patients with rising titers had recurrent disease; but 50%–61% of patients with normal levels also had recurrent or persistent tumor. Therefore, only a change from normal to abnormal or a rising titer is significant. In one study an increase in titer preceded clinical evidence of metastasis or recurrence by an average of 3 months (range, 1-11 months). CA 125 has also been useful to detect ovarian cancer cells in effusions. However, a study based on decision analysis methodology concluded that CA 125 (and ultrasound) were not cost effective as early detection screening tests for ovarian cancer.

    Elevated CA 125 Levels in Various Conditions
    Malignant
    Epithelial ovarian carcinoma, 75%–80% (range, 25%–92%, better in serous than mucinous cystadenocarcinoma)
    Endometrial carcinoma, 25%–48% (2%–90%)
    Pancreatic carcinoma, %
    Colorectal carcinoma, 20% (15%–56%)
    Endocervical adenocarcinoma, %
    Squamous cervical or vaginal carcinoma, 7%–14%
    Lung carcinoma, 32%
    Breast carcinoma, 12%–40%
    Lymphoma, 35%
    Benign
    Cirrhosis, 40%–80%
    Acute pancreatitis, 38%
    Acute peritonitis, 75%
    Endometriosis, 88%
    Acute pelvic inflammation disease, 33%
    Pregnancy 1st trimester, 2%–24%
    During menstruation (occasionally)
    Renal failure (? frequency)
    Normal persons, 0.6%–1.4%

  • Flow Cytometry in Cancer

    FCM has until recently been predominantly used to phenotype leukemias and lymphomas and to aid in prognosis of nonhematologic tumors.

    Nonhematologic tumors

    In nonhematologic tumors, predominately aneuploid neoplasms (especially if the S-phase value is increased) generally are more aggressive and have shorter survival time than tumors that are predominantly diploid and have normal S-phase values. However, this varies considerably between different tumor types, and there is often variation between tumors in different patients with the same tumor type. Added to this are various technical problems, such as mixtures of diploid and aneuploid tumor cells, mixtures of normal cells and tumor cells, differences in degree of tumor anaplasia in different areas, whether the tissue is fresh or formalin-fixed, proper adjustment of the instrumentation, and experience in avoiding or interpreting variant DNA peaks. S-phase work in nonhematologic tumors is more difficult than standard ploidy determination and sometimes cannot be done adequately.

    The most intensively studied (or reported) nonhematologic malignancies have been breast, colorectal, prostate, urinary bladder, ovary, and uterus.

    In breast carcinoma, there has been considerable disagreement between various studies, but overall suggestion that DNA ploidy is not a reliable independent factor in predicting likelihood of lymph node metastasis or length of survival. S-phase analysis is much more difficult to perform adequately but appears to have some predictive value regarding lymph node metastasis, degree of tumor differentiation, and presence of estrogen receptors. In colorectal cancer, the majority of studies have found that aneuploid tumors usually have shorter survival than diploid tumors and there is some correlation with probable Duke’s tumor stage (except for stage D) and therefore overall survival. In early superficial (noninvasive) transitional cell carcinoma of the urinary bladder, degree of aneuploidy has predictive value for invasiveness and tumor grade. FCM on bladder washings has additive value to biopsy of early superficial lesions. If the DNA index (measuring aneuploidy) of the biopsy differs from that of bladder washings before treatment, this suggests higher risk of tumor invasion. If the bladder washing DNA index is aneuploid and that of the biopsy is diploid, this suggests carcinoma in situ. However, if both are aneuploid, there is no prognostic assistance. Bladder washing FCM is considered the best test to follow up a patient after tumor surgery. If intravesical chemotherapy is given, it is necessary to wait 6 months after the last chemotherapy dose to resume bladder washing surveillance (because of chemotherapy-induced abnormalities in normal epithelial cells). Fresh urine specimens are much better than preserved specimens; the fresh specimen should be refrigerated immediately and analyzed as soon as possible, but no more than 12 hours later. If that is not possible, appropriate fixative must be added. In prostate carcinoma, DNA diploid tumors tend to be better differentiated (lower grade), respond better to radiation therapy, and have longer survival time; aneuploid tumors tend to be less differentiated (higher grade) with a worse prognosis and usually have less response to estrogen therapy. In ovarian carcinoma, diploid carcinomas in stage III or less have a much better prognosis than aneuploid carcinomas. In melanoma and in renal, endometrial, bone and cervix carcinomas, diploid state has some chance of a better prognosis.

    Hematopoietic malignancies

    In hematopoietic malignancies, malignant lymphomas that are diploid are usually lower grade and less aggressive, with the opposite generally true for aneuploid lymphomas. However, not all reports agree. S-phase analysis is also said to have prognostic value. Burkitt’s lymphoma has an interesting FCM profile, since it is usually diploid but has a high S-phase value and behaves like a typical aneuploid tumor. Childhood acute lymphocytic leukemia (ALL) that is aneuploid has a better response to chemotherapy. This has not been shown with adult ALL or with acute myelogenous leukemia.

  • Other Conditions Associated with Arthritis

    Arthritis and arthralgia may be present in 4%-23% of patients with primary biliary cirrhosis. One report indicates that many more have radiologic abnormalities of erosive arthritis but have no symptoms. About 50% of patients with hemochromatosis and about 25% of patients with chronic active hepatitis develop arthritis or arthralgias; up to 40% of patients with hepatitis virus hepatitis have arthralgia (usually not true arthritis); and arthritis may occasionally be found in patients with viral infections of various etiology (e.g., rubella). Patients with cancer may develop joint symptoms due to direct extension from or a reaction to a nearby primary site or from joint area metastasis. Joint metastasis usually involves one of the knees and is most often due to carcinoma of the lung or breast. Metastasis to the hand is most often due to lung carcinoma. Childhood acute leukemia rather frequently appears to produce joint pain for a variety of reasons. Neoplasia have been associated with gout, vasculitis, and occasionally, syndromes resembling some of the collagen diseases. Occasionally, there may be arthritic symptoms without neoplastic joint involvement. Sarcoidosis may occasionally produce arthritis.